Malaria has had a greater impact on world history than any other infectious disease, its endemic in over 90 countries in which 2400 million people live; this represents 40% of the world's population. Approximately 90% of malaria deaths occur in Africa . The intensity of transmission ranges from extremely low in Khartoum and the north, to very high in the southwest of the country. Sudan showed a decline in national parasite prevalence from 3.7% in 2000 to 1.8% in 2009. However, subsequent increases to 3.3% in 2012 and 5.4% in 2016 were concerning. Reductions in funding for malaria control, suboptimal coverage of long-lasting insecticide-treated nets and lower rates of malaria testing .
Malaria is a protozoan disease caused by plasmodium parasites transmitted by bite of infected Anopheles mosquitoes. The plasmodium species  are P. falciparum, P. vivax, P. ovale, and P. malariae and almost all deaths are caused by falciparum malaria . The patient presented with headache, malaise, hepatosplenomegaly, anemia, vomiting and Jaundice which is common due to hemolysis. The clinical features of malaria are non-specific and the diagnosis must be suspected in anyone returning from an endemic area who has features of infection. The risk of severe malaria. P. vivax and P. ovale increase with previous splenectomy 
According to World Health Organization (WHO) 2015 about malaria management guidelines; Treatment of children and adults with uncomplicated P. falciparum malaria (except pregnant women in their first trimester) with one of the following recommended ACTs: Artemether + lumefantrine, Artesunate + Amodiaquine, Artesunate + Mefloquine, Dihydroartemisinin + piperaquine, Artesunate + Sulfadoxine–Pyrimethamine (SP). ACT regimens should provide 3 days’ treatment with an Artemisinin derivative. Strong recommendation, high-quality evidence Revised dose recommendation for Dihydroartemisinin + piperaquine in young children weighing <25kg treated with Dihydroartemisinin + piperaquine should receive a minimum of 2.5 mg/kg per day of Dihydroartemisinin and 20 mg/ kg per day of piperaquine daily for 3 days. In areas with chloroquine-susceptible infections, treat adults and children with Uncomplicated P. vivax, P. ovale, P. malariae or P. knowlesi malaria with either an ACT (except pregnant women in their first trimester) or chloroquine. In areas with chloroquine-resistant infections, treat adults and children with Uncomplicated P. vivax, P. ovale, P. malariae or P. knowlesi malaria (except pregnant women in their first trimester) with an ACT. On the other hand the treatment of adults and children with severe malaria -including infants, pregnant women in all trimesters and lactating women- with intravenous or intramuscular artesunate for at least 24 h or until they can tolerate oral medication. Once a patient has received at least 24 h of parenteral therapy and can tolerate oral therapy, complete treatment with 3 days of an ACT (add single dose Primaquine in areas of low transmission) 
The aim of this study to assess the knowledge about malaria management guidelines among house officers in Khartoum state teaching hospital.